Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABLYSINOL vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Empiric therapy for presumed fungal infection in febrile neutropenic patients,Treatment of systemic fungal infections (e.g., aspergillosis, candidiasis, cryptococcosis),Treatment of visceral leishmaniasis
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Ivermectin is metabolized primarily by CYP3A4 to hydroxylated and demethylated metabolites. Phase II glucuronidation may occur. No active metabolites are identified.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; the remaining 10% is metabolized.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Volume of distribution is 0.5 L/kg, indicating distribution primarily into extracellular fluid.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Oral bioavailability is 40–50% due to first-pass metabolism; intramuscular bioavailability is 80%.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: not recommended.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Not approved for use in pediatric patients.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
No specific dose adjustment; monitor for increased sensitivity and renal function.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
This drug should be used primarily for treatment of progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of disease (e.g., oral thrush, vaginal candidiasis).
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Monitor renal function closely; may cause dose-dependent nephrotoxicity. Premedicate for infusion reactions (fever, chills, rigors). Monitor electrolytes (hypokalemia, hypomagnesemia). Risk of cardiotoxicity with rapid infusion. Use caution in patients with renal impairment; dose adjustment required.
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Hypersensitivity to amphotericin B or any component of the formulation, unless the benefit outweighs the risk.
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Avoid grapefruit and grapefruit juice as they may increase fingolimod concentrations. No specific dietary restrictions, but maintain adequate hydration.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, premature closure of ductus arteriosus, and neonatal renal impairment.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Contraindicated. Excreted in human milk; M/P ratio not determined. Potential for serious adverse reactions in breastfed infants.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Increased renal clearance in pregnancy may require dose increments of 30-50% to maintain therapeutic levels; monitor serum lithium concentrations and adjust dose to therapeutic range (0.6-1.2 m Eq/L).
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
ABLYSINOL (fingolimod) is a sphingosine-1-phosphate receptor modulator used for relapsing forms of multiple sclerosis. First-dose monitoring for bradycardia (6 hours) is mandatory; consider pre-treatment ECG. Avoid live vaccines during and for 2 months after therapy. Monitor for macular edema (ophthalmologic exam at baseline and 3-4 months). Lymphopenia is expected; check CBC before initiation and periodically. Drug interactions: QTc-prolonging agents, immunosuppressants, beta-blockers, calcium channel blockers. Do not use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Stay hydrated and avoid grapefruit juice; it may increase drug levels.,Report any vision changes, slow heartbeat, or dizziness immediately.,Avoid pregnancy; use effective contraception during and for 2 months after stopping.,Do not receive live vaccinations during treatment.,Take exactly as prescribed; do not skip doses or stop suddenly.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABLYSINOL vs ALFENTANIL, answered by our medical review team.
ABLYSINOL is a Calcineurin inhibitor that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABLYSINOL and ALFENTANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABLYSINOL is: Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABLYSINOL and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABLYSINOL is classified as Category C. Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, p. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.